Workflow
Rylaze
icon
Search documents
Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data
Yahoo Finance· 2025-10-02 05:53
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the stocks with low beta that can beat market volatility. On September 23, Morgan Stanley reaffirmed its Overweight rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and raised its price target from $163 to $167. The adjustment came after Jazz Pharmaceuticals plc (NASDAQ:JAZZ) revealed findings from the Xywav Phase 4 DUET open-label research at World Sleep Singapore through many poster presentations. The study’s findings indicate that oxybates, the family ...
Jazz Pharmaceuticals(JAZZ) - 2025 Q2 - Earnings Call Presentation
2025-08-05 20:30
Financial Performance - Total revenues reached $761 million in 2Q25, a 2% year-over-year increase[93] - Neuroscience revenues accounted for 43% of the total, amounting to $335 million in 2Q25[98] - Oncology revenues totaled $274 million in 2Q25[100] - The company updated its full-year 2025 revenue guidance to a range of $415 billion to $430 billion[30, 36] - The company projects non-GAAP adjusted net income to be in the range of $300 million to $350 million, with adjusted EPS between $480 and $560[36] Product Performance - Xywav revenues were $415 million in 2Q25, representing a 13% year-over-year growth[100] - Epidiolex revenues reached $252 million in 2Q25, a 2% year-over-year increase[100] - Rylaze revenues were $101 million in 2Q25, a 7% year-over-year decrease[53] - Zepzelca revenues were $75 million in 2Q25, an 8% year-over-year decrease[59] Pipeline and Corporate Development - The company closed the Chimerix Acquisition for a total consideration of $944 million[32, 33] - The acquisition of Chimerix included an acquired IPR&D expense of $9054 million related to dordaviprone[23, 94, 113] - A PDUFA target action date of October 7, 2025, was set for Zepzelca as maintenance therapy in 1L ES-SCLC[35, 61, 62]
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Prnewswire· 2025-07-10 11:30
Core Viewpoint - Jazz Pharmaceuticals has announced the appointment of Renee Gala as the new President and CEO, effective August 11, 2025, succeeding co-founder Bruce Cozadd, who will remain as Chairperson of the Board [1][3]. Company Leadership Transition - The Board of Directors conducted a thorough search for the new CEO, focusing on both internal and external candidates, ultimately selecting Renee Gala due to her exceptional leadership qualities and experience [3]. - Bruce Cozadd, who has been with the company for 22 years, expressed pride in the company's journey and confidence in Gala's ability to lead Jazz into its next growth phase [3][4]. Renee Gala's Background - Renee Gala has over 30 years of experience in finance, strategy, corporate development, and commercialization, having served as CFO and COO at Jazz Pharmaceuticals since 2020 and 2023, respectively [2][4]. - Prior to joining Jazz, Gala held leadership roles at GRAIL Inc. and Theravance Biopharma, showcasing a strong background in the life sciences sector [4][5]. Company Strategy and Vision - Gala emphasized the company's commitment to transforming patient lives through innovative medicines and highlighted the potential for growth within Jazz's market-leading portfolio and promising pipeline [3][6]. - The company aims to continue its focus on corporate development and external innovation to drive value for patients and shareholders [3][6].
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
ZACKS· 2025-05-06 23:30
Core Insights - Jazz Pharmaceuticals reported revenue of $897.84 million for Q1 2025, a year-over-year decline of 0.5% and an EPS of $1.68, down from $2.68 a year ago, indicating significant underperformance against analyst expectations [1] - The revenue fell short of the Zacks Consensus Estimate of $981.41 million by 8.52%, while the EPS was 62.75% below the consensus estimate of $4.51 [1] Revenue Breakdown - Royalties and contract revenues were $58.42 million, slightly above the estimated $56.30 million [4] - Product sales, net, were $839.42 million, compared to the average estimate of $925.39 million, reflecting a year-over-year change of -0.3% [4] - Total revenues from Neuroscience for Oxybate (Xywav) were $344.80 million, below the estimate of $377.35 million, with a year-over-year increase of 9.4% [4] - Revenues from Epidiolex/Epidyolex totaled $217.74 million, compared to the estimate of $233.21 million, marking a 9.6% increase year-over-year [4] - Sativex revenues were $5.41 million, exceeding the estimate of $3.79 million, with a significant year-over-year increase of 97.7% [4] - Total Neuroscience revenues were $605.19 million, below the estimate of $652.54 million, with a year-over-year increase of 4.2% [4] - Total Oncology revenues were $229.45 million, below the estimate of $269.04 million, reflecting a year-over-year decline of 10.9% [4] - Rylaze revenues were $94.23 million, below the estimate of $104.20 million, with an 8.3% decline year-over-year [4] - Revenues from Defitelio/defibrotide were $40.66 million, below the estimate of $47.89 million, representing a 14.7% year-over-year decline [4] - Vyxeos revenues were $29.54 million, below the estimate of $34.56 million, with a year-over-year decline of 7.7% [4] - Zepzelca revenues were $63.03 million, below the estimate of $80.75 million, reflecting a year-over-year decline of 16.1% [4] Stock Performance - Jazz Pharmaceuticals' shares returned +10.5% over the past month, compared to the Zacks S&P 500 composite's +11.5% change, indicating a performance in line with the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]
Jazz Pharmaceuticals(JAZZ) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:21
Financial Performance & Guidance - Total revenues are projected to be between $4.15 billion and $4.40 billion, representing approximately 5% growth at the guidance midpoint[26] - The company anticipates Non-GAAP Adjusted Net Income (ANI) to be in the range of $250 million to $350 million[27] - Adjusted EPS is expected to be between $4.00 and $5.60[27] - The company had a strong operating cash flow of $430 million in 1Q25 and cash reserves of $2.6 billion at the end of 1Q25[27] - 1Q25 Non-GAAP ANI decreased 41% YoY to $105 million, and EPS decreased 36% YoY to $1.68, impacted by Xyrem antitrust litigation settlements[92] Product Performance - Xywav revenues grew 9% YoY in 1Q25, with Xywav remaining the 1 branded treatment for narcolepsy and the only therapy approved to treat Idiopathic Hypersomnia (IH)[24] - Epidiolex revenues increased 10% YoY in 1Q25 and is poised to reach blockbuster status in 2025[24, 40, 43] - Oncology revenues declined 11% YoY in 1Q25, impacted by SCLC competition for Zepzelca and COG protocol changes impacting Rylaze[24] - Total sleep therapeutic area revenue was $431 million in 1Q25[34] Pipeline Development - Zanidatamab is considered a near-term opportunity with a potential market opportunity exceeding $2 billion[5, 74] - Dordaviprone has a PDUFA action date of August 18, 2025, representing a near-term commercial opportunity[22, 87, 118]
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
ZACKS· 2025-04-30 12:20
Core Viewpoint - Jazz Pharmaceuticals is expected to report first-quarter 2025 earnings on May 6, with sales estimated at $978.6 million and earnings at $4.61 per share, reflecting a positive trend in earnings estimates for 2025 [1][3]. Financial Performance - Jazz Pharmaceuticals has exceeded earnings expectations in three of the last four quarters, with a trailing four-quarter average earnings surprise of 3.20% and a notable earnings surprise of 13.99% in the last quarter [3]. - The company currently has an Earnings ESP of -2.75% and a Zacks Rank of 3 (Hold) [5]. Revenue Segments - The company reports financial figures under two segments: Neuroscience and Oncology. The consensus estimate for neuroscience product sales is $649 million, while the estimate for oncology sales is $269 million [7][10]. - Sales of the sleep disorder drug Xywav are projected at $372 million, with expectations of continued growth due to its uptake in narcolepsy and idiopathic hypersomnia [8]. - Epidiolex sales are expected to rise to $234 million, driven by geographic expansion, while sales of the legacy drug Xyrem are anticipated to decline [9]. Oncology Performance - Sales of the chemotherapy drug Rylaze are expected to be impacted by recent updates to treatment protocols, with estimates pegged at $103 million [11]. - Other oncology drugs, including Zepzelca, Vyxeos, and Defitelio, are expected to grow at a mid-single-digit percentage during the quarter [11]. Stock Performance and Valuation - Jazz Pharmaceuticals' shares have declined about 6% year-to-date, compared to a 4% decline in the industry, and are currently trading below their 50-day and 200-day moving averages [13]. - The stock is trading at a price-to-sales (P/S) ratio of 1.76, lower than the industry average of 1.97 and below its five-year mean of 2.70, indicating a valuation discount [16]. Investment Thesis - The company has a diversified portfolio in neuroscience and oncology, although pipeline setbacks, such as the discontinuation of suvecaltamide development, pose concerns [18]. - Strategic acquisitions have bolstered the pipeline, with five oncology products marketed and an FDA decision on a sixth product expected by August 18 [19][20]. - Despite challenges, the rising EPS estimates for 2025 and a robust cash reserve of $3.0 billion at the end of 2024 provide reasons to remain invested in Jazz Pharmaceuticals [21].
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
ZACKS· 2025-03-10 13:46
Core Insights - The article emphasizes the growing popularity of value investing as investors seek strategies that assess a stock's inherent potential amidst market volatility [1][2] - Warren Buffett's perspective on understanding a stock's "intrinsic value" is highlighted as a means to mitigate common pitfalls in value investing [2] - The article discusses four stocks that have recently performed well under a value investment strategy: Molson Coors Beverage, BioMarin Pharma, Devon Energy, and Jazz Pharmaceuticals [3] Value Investment Strategy - Value investing is gaining traction, but it can lead to "value traps" if investors do not fully understand the strategy [4] - Key metrics for identifying value stocks include dividend yield, P/E ratio, and P/B ratio, which help determine if a stock is undervalued [4] Importance of Earnings Growth - Investors are advised to focus on a stock's earnings growth potential over the next 12 to 24 months to avoid value traps [5] - The PEG ratio, which considers both price/earnings and earnings growth rate, is presented as a valuable metric for assessing intrinsic value [6] Screening Criteria for Value Stocks - Effective screening criteria for identifying promising value stocks include: - PEG Ratio less than industry median - P/E Ratio less than industry median - Zacks Rank 1 or 2 - Market Capitalization greater than $1 billion - Average 20-Day Volume greater than 50,000 - Percentage Change in F1 Earnings Estimate Revisions greater than 5% - Value Score of A or B [7] Featured Stocks - **Molson Coors Beverage (TAP)**: Holds a Zacks Rank 1, Value Score of A, and a five-year expected growth rate of 6.3% [8][9] - **BioMarin Pharma (BMRN)**: Has a Zacks Rank 2, Value Score of B, and a long-term historical growth rate of 77.6% [9][10] - **Devon Energy (DVN)**: Carries a Zacks Rank 2, Value Score of A, and a five-year historical growth rate of 40.1% [10][11] - **Jazz Pharmaceuticals (JAZZ)**: Holds a Value Score of A, Zacks Rank 1, and an expected long-term earnings growth rate of 7.4% [11][12]